IFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

NISHIDA ET AL.

Serial No. 10/575,872

Filed: April 14, 2006

For: REGENERATIVE MEDICAL TREATMENT SYSTEM

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 Group: Unknown

Atty. Ref.:

Examiner: Unknown

159-101

August 16, 2007

Sir:

INFORMATION DISCLOSURE STATEMENT

 \boxtimes 1. **PTO-1449 Pursuant to 37 CFR 1.97(b)** [within 3 months of filing or prior to 1st Office Action on the merits] N/C 2.(a) Statement Pursuant to 37 CFR 1.97(c) [before Final Office Action or Allowance (requires Rule 97(e) Statement or Rule 17(p) fee)] N/C 2 .(b) Fee Payment Pursuant to 37 CFR 1.97(c) [before Final Office Action or Allowance (requires Rule 97(e) Statement or Rule 17(p) fee)] \$180.00 3. Pursuant to 37 CFR 1.97(d) [after Final Office Action or Allowance (requires Rule 97(e) Statement and Rule 17(p) fee), but before final fee payment] \$180.00

The following are submitted in the above-identified application in compliance with 37 C.F.R. §§ 1.97 and 1.98:

⊠	4.	iden eacl	t of documents on Form PTO-1449 together with copies of each tified document and a translation or a concise explanation of non-English language document (such as a Search Report) is osed herewith.					
Γhis p	aper i	s sub	mitted in accordance with:					
\boxtimes	5.	37 C	CFR 1.97(b): [within 3 months of filing or prior to 1st Office Action]					
	6.	37 CFR 1.97(c): [before Final Office Action or Allowance, whichever is earlier] and						
		a)	The required Statement made in item 8 below; or					
		b)	The \$180.00 fee specified in 37 CFR §1.17(p) for submission of this Information Disclosure Statement is authorized in item 9 below.					
	7.	37 CFR §1.97(d): [after Final Office Action or Allowance (requires Rule 97(e) Statement and Rule 17(p) fee), but before final fee payment]; and						
		a)	The fee (\$180.00) required by 37 CFR §1.17(p) is submitted herewith; and					
		b)	The required Statement is stated in item 8 below.					
	8.	Stat	ement under 37 CFR 1.97(e)					
		a)	The undersigned attorney of record hereby certifies under 37 C.F.R. §1.97(e) that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement (each item contained in this IDS was the first citation of that item by a foreign patent office in a counterpart foreign application which occurred no more than three months prior to the filing of this IDS); or					
		b)	No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement, after making reasonable inquiry, no item of information contained in this Statement was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.					

NISHIDA ET AL. Serial No. 10/575,872

9. Please charge all deficiency fees associated with the submission of this Information Disclosure Statement and any other fees applicable to this application to Deposit Account No. 14-1140. An original and one (1) copy of this document are enclosed.

Respectfully submitted, NIXON & VANDERHYE P.C.

By:

3. J) Sadoff

Reg. No. 36,663

901 North Glebe Road, 11th Floor

Arlington, VA 22203-1808 Telephone: (703) 816-4000 Facsimile: (703) 816-4100

Sheet	1	of	1'	
CHICCE		U .		

INFORMATION DISCLOSURE CITATION

ATTY, DOCKET NO.

159-101

APPLICANT

SERIAL NO.

AUG 16 2007

10/575,872

NISHIDA ET AL

(Us	e several sheets if necessary)	NISHIDA ET AL.								
•	•	April 1	4, 2006	Unknown	Unknown					
		U.S.	PATENT DOCUMENTS							
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS SUBCLASS		FILING DATE IF APPROPRIATE				
	2003/0152558	08/2003	Luft et al							
		+								
					<u> </u>					
		FORE	IGN PATENT DOCUMENT	S	I	L				
							LATION			
	DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	YES	NO			
	WO 03/080801	10/2003	WIPO							
							[
	 	+		<u></u>			 			
	OTHER DOCUM	IENTS (inc	luding Author, Title, Date,	Pertinent pa	aes. etc.)	1			
	Cheng et al, "Human Adult Marrow Cells Support Prolonged Expansion of Human Embryonic Stem Cells in Culture", Stem Cells, 2003; 21:131-142 Aoki et al, "Coculture of Endothelial Cells and Mature Adipocytes Actively Promotes Immature Preadipocyte Development In Vitro", Cell Structure and Function, 2003; 28:55-6 Richards et al, "Comparative Evaluation of Various Human Feeders for Prolonged Undifferentiated Growth of Human Embryonic Stem Cells", Stem Cells, 2003; 21:546-556 Papini et al, "Isolation and Clonal Analysis of Human Epidermal Keratinocyte Stem Cells in Long-Term Culture", Stem Cells, 2003; 21;481-494 Hovatta et al, "A Culture System Using Human Foreskin Fibroblasts as Feeder Cells Allow Production of Human Embryonic Stem Cells", Human Reproduction, 2003, Vol. 18, No. 7, pp 1404-1409 Amit et al, "Human Feeder Layers for Human Embryonic Stem Cells", Biology of Reproduction, 2003; 68, 2150-2156 Mizuno e al, "Mesengenic Potential and Future Clinical Perspective of Human Processed Lipoaspirate Cells", J Nippon Med Sch, 2003; 70(4) 300-306 Database Medline, U.S. National Library of Medicine (NLM), Bethesda, MD, US; July 2003 Ramaesh et al: "Ex vivo expansion of corneal limbal epithelial/stem cells for corneal surface									
	I COOTION GONOTI X	. 502 10002	23, Database Accession No.	142101204001						
*Evaminas			Data Cassidared							
*Examiner			Date Considered							

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)